Our easy-to-read patient fact sheet compares and contrasts sinus arrhythmia vs AFib (atrial fibrillation) symptoms.
Milestone Pharmaceuticals Inc. announced that the PDUFA date for its nasal spray CARDAMYSTâ„¢ (etripamil) for treating Paroxysmal Supraventricular Tachycardia (PSVT) has been set for March 27, 2025.
Each year, more than 454,000 people in the U.S. are hospitalized with atrial fibrillation, the most common type of treated heart arrhythmia. It also contributes to 158,000 deaths each year. Perhaps ...
If you have symptoms of Afib, you should promptly inform your doctor, who can diagnose it with an electrocardiogram (EKG), a quick test that is typically part of an annual health checkup.
Commercial capabilities build out in process, with proposed launch in PSVT targeted for mid-2025 - Plans to initiate Phase 3 Study in AFib-RVR in H1 2025 MONTREAL and CHARLOTTE, N.C., Jan. 28 ...
The study included patients with atrial fibrillation (AF) and valvular heart disease, excluding those with mechanical heart valves. Patients with AF associated with mechanical heart valves and ...
Etripamil for patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) Phase 3 pivotal trial in AFib-RVR expected to begin enrollment in H1 2025. Milestone plans to initiate a ...
NEW HAVEN, Conn. (WTNH) — In Friday’s Health headlines, February is heart month, and we’re talking about AFib, portable EKG devices, and how stress this season can be hard on the heart.
In Friday’s Health headlines, February is heart month, and we’re talking about AFib, portable EKG devices, and how stress this season can be hard on the heart. Yale Medicine electrocardiologist Dr.
Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation. One of the core results from AZALEA-TIMI 71 ...
Atrial fibrillation (AFib) is the most common form of irregular heartbeat (arrhythmia). People with AFib have many treatment options, including medications and medical procedures. However ...